Phase 4 N=25 Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD)
Generalized Anxiety Disorder
Primary: Change in Hamilton Anxiety Rating Scale Score — -6.4 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=45 Study of Myfortic in Combination With Tacrolimus and Thymoglobulin in Early Corticosteroid Withdrawal
End Stage Renal Disease (ESRD)
Primary: Incidence of All Biopsy Proven Acute Rejection. — 1; 4 Participants
Phase 4 N=1,347 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
Trachoma · Chlamydia Trachomatis
Primary: Infection With Chlamydia Trachomatis Diagnosed by Use of NAATs [Nucleic Acid Amplification Test] — 57; 42; 5; 3 Participants
Phase 4 N=155 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.
Hepatitis C, Chronic
Primary: Change From Initiation of Pegasys Plus Copegus in log10 Hepatitis C Virus Ribonucleic Acid (HCV RNA) Viral Load to Week 12 of Anti-HCV Therapy — -3.5; -3.7 IU/mL
Phase 4 N=36 Oral Contraceptives in the Metabolic Syndrome
Metabolic Syndrome X · Insulin Resistance · Obesity
Primary: Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women — 4.36; 6.62; 3.82; 8.23 mIU/L
Phase 4 N=120 Post Operative Sore Throat and Dexamethasone
Sore Throat · Pain
Primary: Subjects Assessment of Sore Throat Pain at 24 Hours — 4; 4; 5 units on a scale (1 to 5) — p=<0.001
Phase 4 N=38 Patellar Resurfacing Versus Patellar Retention in Total Knee Arthroplasty - A Randomized Clinical Trial
Total Knee Replacement
Primary: Change in Western Ontario MacMaster (WOMAC) Osteoarthritis Index Pain Score From Preoperative to 5 Years Postoperative — 34.7; 39.2 units on a scale — p=0.59
Phase 4 N=328 Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia
Primary Dyslipidemia · Mixed Dyslipidemia
Primary: Mean Percent Change in Low Density Lipoprotein Cholesterol(LDL-C) From Baseline to Week 12 — -34.8; -22.7 percent
Phase 4 N=94 Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Major Abdominal Surgery
Biliary Tract Surgical Procedures · Pancreaticoduodenectomy · Esophagectomy
Primary: Post-operative Blood Loss — 394.3; 494.3 milliliter (mL) — p=0.460
Phase 4 N=20 Ologen Collagen Matrix Safety and Effective Comparison With Mitomycin-C(MMC) in Glaucoma Surgery
Open Angle Glaucoma
Primary: Postoperative Intraocular Pressure Change — -11.3; -11.6 mm Hg — p=0.95
Phase 4 N=34 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
Cancer
Primary: Plasma Pazopanib Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 Hours (AUC[0-24]) of Pazopanib Alone and of Pazopanib in Combination With…
Phase 4 N=231 Effects of Travatan Z and Xalatan on Ocular Surface Health
Glaucoma · Ocular Hypertension
Primary: Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break Up Time (TBUT) — 0.8; 1.1 seconds
Phase 4 N=31 Adipokines in Obese Adolescents With Insulin Resistance
Obesity
Primary: Adiponectin — -0.71; -7.52 µg/mL
Phase 4 N=273 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis
Plaque Psoriasis · Psoriasis
Primary: Percentage of Participants Achieving a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 24 — 78.2; 59.9 Percentage of participants…
Phase 4 N=236 Examination of Ocular Surface Effects With Administration of Travatan Z and XALATAN
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change at 12 Weeks (Day 84) From Baseline (Day 0) in Tear Film Break-Up Time (TFBUT) — 0.7; 0.6 Seconds